PROGRAM
Please note that the program and presentation titles are subject to change. Click on the "+" to expand.
Wednesday, March 25, 2020
| Time | Program | Chair(s) | Invited Speakers | |
| 13:00-17:00 | ITONF at iMig Nursing Workshop | Liz Darlison Buerkley Rose | ||
| 13:00-13:30 | Registration, Refreshments & Poster Viewing | |||
| 13:30-13:40 | Welcome to ITONF at iMig Nursing Workshop | Maria Guerin | ||
| 13:40-14:10 | Standardising Nursing Procedures – An Overview of Nursing in Mesothelioma and Nursing Models Across the Globe | Melissa Culligan | ||
| 14:10-14:40 | Mesothelioma Patients’ Experiences of Follow-up Care | Catherine Henshall | ||
| 14:40-15:10 | Mesothelioma Clinical Trial Landscape 2020+ | Buerkley Rose | ||
| 15:10-15:30 | Refreshments & Poster Viewing | |||
| 15:30-16:00 | Case Study: Global Perspectives: Presentation, Treatment & Care Including the Medico-Legal Aspects | Jocelyn McLean | Mary Duffy (AUS) Buerkley Rose (USA) Anne Moylan (UK) Phemelo Magabanyane (South Africa) | |
| 16:00-16:30 | Plenary: End of Life Care | Janet Hardy | ||
| 16:30-16:37 | Evaluation of Mesothelioma in a Large District General Hospital in the UK 2017 - 2018. A Retrospective Case Note Audit | Anne Moylan | ||
| 16:37-16:44 | What are the Psychological Effects of Meso on Patients and Their Carers? A Scoping Collaboration | Anne Moylan | ||
| 16:44-16:51 | Supporting Our Armed Forces. Raising Awareness and Providing Information and Support for Veterans/Armed Forces Personnel | Helen Wilkes | ||
| 16:51-16:58 | Non-NHS Funded Therapy vs Clinical Trials: The Importance of Patient Autonomy in Mesothelioma Treatment Decision Making | Simon Bolton | ||
| 16:58-17:05 | Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Mesothelioma. Do We Really Need Emotional Support Groups? | Arooj Fatima | ||
| 17:05-17:10 | Summary & Close | Liz Darlison | ||
| 14:00-17:00 | 14:00-17:00 | Mesothelioma in East Asia | Ken Takahashi Takashi Kijima | |
| 14:00-14:10 | Welcome | Takashi Kijima | ||
| 14:10-14:30 | Keynote: Mesothelioma in East Asia "The Asian Mesothelioma Epidemic" | Ken Takahashi | ||
| 14:30-14:45 | Hand-spining Chrysotile Exposure and Mesothelioma in Southeastern China | Jianlin Lou | ||
| 14:45-15:00 | The Consumption of Asbestos and the Incidence of Mesothelioma in China | Rongshou Zheng | ||
| 15:00-15:10 | Abstract by selection | |||
| 15:10-15:20 | Discussion / Q&A | |||
| 15:20-15:35 | Break | |||
| 15:35-15:55 | Keynote: Nivolumab for malignant mesothelioma: a real-word experience | Takashi Kijima | ||
| 15:55-16:05 | Abstract by selection | |||
| 16:05-16:15 | Abstract by selection | |||
| 16:15-16:25 | Abstract by selection | |||
| 16:25-16:40 | Discussion / Q&A | |||
| 16:40-16:50 | Summary & Closing | Ken Takahashi |
Thursday, March 26, 2020
| Time | Program | Chairs | Invited Speakers | |
| 8:30-8:45 | 8:30-8:45 | Opening Address | ||
| 8:45-10:15 | 8:45-10:15 | Plenary I: Origins of Mesothelioma | Jim teWaterNaude Ken Takahashi | |
| 8:45-9:00 | The Global Mesothelioma Epidemic and Control Strategies | Ken Takahashi | ||
| 9:00-9:15 | Disasters and Asbestos Exposure | Dave Hodgkin | ||
| 9:15-9:30 | Mesothelioma in Situ | Sonja Klebe | ||
| 9:30-9:45 | Germline and Somatic Mutations in Mesothelioma | Jane Churpek | ||
| 9:45-9:55 | Abstract by selection | |||
| 9:55-10:05 | Abstract by selection | |||
| 10:05-10:15 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 1: Pathology | Sonja Klebe | |
| 11:00-11:15 | As Pathologist What Have We Learned from Deep Learning for the Diagnostic or Pronostic of Mesothelioma | Francoise Galateau-Salle | ||
| 11:15-11:30 | RNA Seq and Molecular Classification of Mesothelioma- How Does It Impact Practice? | Ann-Marie Patch | ||
| 11:30-11:40 | Abstract by selection | |||
| 11:40-11:50 | Abstract by selection | |||
| 11:50-12:00 | Abstract by selection | |||
| 12:00-12:10 | Abstract by selection | |||
| 12:10-12:20 | Abstract by selection | |||
| 12:20-12:30 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 2: Clinical Trials | Peter Szlosarek Morgan Windsor | |
| 11:00-11:15 | Overview of Clinical Trial in Medical Oncology | Hedy Kindler | ||
| 11:15- 11:30 | Clinical Trials in Surgery | Loic Lang-Lazdunski | ||
| 11:30-11:40 | Abstract by selection | |||
| 11:40-11:50 | Abstract by selection | |||
| 11:50-12:00 | Abstract by selection | |||
| 12:00-12:10 | Abstract by selection | |||
| 12:10-12:20 | Abstract by selection | |||
| 12:20-12:30 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 3: Local and Intrapleural Therapies | Robert Rintoul Gavin Wright | |
| 11:00-11:15 | Where Are the Intrapleural Therapies? | Daniel Sterman | ||
| 11:15-11:30 | Photodynamic Therapy: Where Is It Now? Can It Enhance Visceral Pleurectomy in RPD? Is It an Enabler for Immunotherapy? | Simon Knight | ||
| 11:30-11:45 | Take or Spare the Lung for Low Volume Stage I Disease - Is There a Correct Approach? | Joseph Friedberg | ||
| 11:45-12:00 | Proton Therapies for Mesothelioma | Charles Simone | ||
| 12:00-12:10 | Abstract by selection | |||
| 12:10-12:20 | Abstract by selection | |||
| 12:20-12:30 | Discussion | |||
| 13:45-15:15 | 13:45-15:15 | Parallel Mini-Symposia 4: Surgery | Andrea Wolf Marc de Perrot | |
| 13:45-14:00 | Ultimate Surgical Selection and Staging | Seiki Hasegawa | ||
| 14:00-14:15 | How Far Should We Go to Obtain Complete Macroscopic Resection? Is EPP Ever Necessary? | Naveed Alam | ||
| 14:15-14:30 | Has the Toronto SMART Protocol Resurrected EPP? Should This Be the Only Indication? | Marc de Perrot | ||
| 14:30-14:45 | Technical Tips to Achieve Complete Visceral Pleurectomy and Reduce Air Leak | Nicolaos Panagiotopoulos | ||
| 14:45-14:55 | Abstract by selection | |||
| 14:55-15:05 | Abstract by selection | |||
| 15:05-15:15 | Abstract by selection | |||
| 13:45-15:15 | 13:45-15:15 | Parallel Mini-Symposia 5: Cell Therapies and Mesothelin Directed Therapies | Steven Kao Nick Pavlakis | |
| 13:45-14:00 | Mesothelioma as a Target for Adoptive T Cell Therapy/T Cell Therapies and Vaccine | Edmund Moon | ||
| 14:00-14:15 | Mesothelin Targeted Therapy | Raffit Hassan | ||
| 14:15-14:30 | What’s All the Buzz about Car-T in the US? About Car-T, Patient Care, Toxicities, and Nursing Considerations for Pleural and Peritoneal Patients | TBC | ||
| 14:30-14:40 | Abstract by selection | |||
| 14:40-14:50 | Abstract by selection | |||
| 14:50-15:00 | Abstract by selection | |||
| 15:00-15:15 | Discussion | |||
| 13:45-15:15 | 13:45-15:15 | Parallel Mini-Symposia 6: Nursing and Supportive Care | Liz Darlison Buerkley Rose | |
| 13:45-14:00 | Patient Experiences in the MARS 2 Study | Liz Darlison | ||
| 14:00-14:15 | Advocacy, Asbestos and South Africa | Tracey Wood | ||
| 14:15-14:30 | Body Composition, Diet and Exercise in People with Mesothelioma | Carolyn McIntyre | ||
| 14:30-14:40 | Abstract by selection | |||
| 14:40-14:50 | Abstract by selection | |||
| 14:50-15:00 | Abstract by selection | |||
| 15:00-15:15 | Discussion | |||
| 16:00-17:30 | 16:00-17:30 | Plenary II: Focus on the Patient | Takashi Nakano Paul Baas | |
| 16:00-16:15 | Symptom Burden in MPM | Fraser Brims | ||
| 16:15-16:30 | Surgical Approaches for Managing Symptoms in Pleural Disease | John Edwards | ||
| 16:30-16:45 | The IPC - Now Standard Care? | Gary Lee | ||
| 16:45-16:55 | Abstract by selection | |||
| 16:55-17:05 | Abstract by selection | |||
| 17:05-17:15 | Abstract by selection | |||
| 17:15-17:30 | Discussion |
Friday, March 27, 2020
| Time | Program | Chairs | Invited Speakers | |
| 7:30-8:15 | 07:30-08:15 | Reports of the Surgical Workshop | Joseph Friedberg | |
| 8:15-8:45 | 8:15-8:45 | Morning Session I | Ken O'Byrne Sam Armato | |
| 8:45-10:15 | 8:45-10:15 | Plenary III: Surgery – Individualising Care Appropriately | Joseph Friedburg Walter Weder | |
| 8:45-9:00 | Is Biphasic an Independent Entity or Do We Need Extensive Sampling to Predict the % of Sarcomatoid Which May Influence Selection | Francoise Galateau-Salle | ||
| 9:00-9:15 | Can Surgery Be Delayed or Avoided Altogether in Patients with Good Response to Induction Chemotherapy, Especially in Elderly Patients? | Isabelle Opitz | ||
| 9:15-9:30 | The Surgical Patient, Trials, Care, Support, Outcomes? | Melissa Culligan | ||
| 9:30-9:45 | Window of Opportunity in Immunotherapy | Arnaud Scherpereel | ||
| 9:45-9:55 | Abstract by selection | |||
| 9:55-10:05 | Abstract by selection | |||
| 10:05-10:15 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 7: Immunotherapy and Checkpoint Blockade | Luciano Mutti Joost Lesterhuis | |
| 11:00-11:15 | Immunotherapy Targets Moving Forward | Luana Calabro | ||
| 11:15-11:30 | Biomarkers for Response to Immunotherapy | Joachim Aerts | ||
| 11:30-11:45 | Epigenetic Remodelling to Improve the Efficacy of Immunotherapy | Alessia Covre | ||
| 11:45-11:55 | Abstract by selection | |||
| 11:55-12:05 | Abstract by selection | |||
| 12:05-12:15 | Abstract by selection | |||
| 12:15-12:30 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 8: Peritoneal Mesothelioma | Sanjeev Naidu | |
| 11:00-11:15 | Peritoneal Debulking Surgery | Nicholas Lutton | ||
| 11:15-11:30 | Does HIPEC Have a Role in Management of Intraperitoneal Disease | Tom Cecil | ||
| 11:30-11:45 | Immunotherapy and Immunochemotherapy in Peritoneal Mesothelioma | Ken O'Byrne | ||
| 11:45-11:55 | Abstract by selection | |||
| 11:55-12:05 | Abstract by selection | |||
| 12:05-12:15 | Abstract by selection | |||
| 12:15-12:30 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 9: Symptoms and Pleural Management | Sjaak Burgers Fraser Brims | |
| 11:00-11:15 | Symptom Burden in Mesothelioma - Pharmacological and Non-pharmacological Management | David Currow | ||
| 11:15-11:30 | Pleurodesis - Updates and Advances | Nick Maskell | ||
| 11:30-11:45 | The Role of the Clinical Nurse Specialist in the Patient Journey | Liz Darlison | ||
| 11:45-11:55 | Abstract by selection | |||
| 11:55-12:05 | Abstract by selection | |||
| 12:05-12:15 | Abstract by selection | |||
| 12:15-12:30 | Discussion | |||
| 13:45-15:15 | 13:45-15:15 | Parallel Mini-Symposia 10: Biomarkers and Genetics | Glen Reid Jenette Creaney | |
| 13:45-14:00 | RNA as a Biomarker | Oluf Dimitri Roe | ||
| 14:00-14:15 | Companion Biomarkers for Novel Targets | Michelangelo Campanella | ||
| 14:15-14:30 | miRNA in Mesothelioma | Glen Reid | ||
| 14:30-14:45 | Chromosomal Rearragements and Neoantigen Expression | Peikert Tobias | ||
| 14:45-14:55 | Abstract by selection | |||
| 14:55-15:05 | Abstract by selection | |||
| 15:05-15:15 | Abstract by selection | |||
| 13:45-15:15 | 13:45-15:15 | Parallel Mini-Symposia 11: Management Decisions in Mesothelioma | Jeremy Steele Edwina Duhig | |
| 13:45-14:00 | The Impact of Histopathological Subtypes of Mesothelioma on Decision Making for Systemic and Immunotherapy in 2020 | Jennifer Sauter | ||
| 14:00-14:15 | Mesothelioma Patients’ Experiences of Follow-up Care | Catherine Henshall | ||
| 14:15-14:30 | Mesothelioma in the Elderly: Frailty and Cognitive Function | TBC | ||
| 14:30-14:40 | Abstract by selection | |||
| 14:40-14:50 | Abstract by selection | |||
| 14:50-15:00 | Abstract by selection | |||
| 15:00-15:15 | Discussion | |||
| 13:45-15:15 | 13:45-15:15 | Parallel Mini-Symposia 12: Imaging | Sam Armato Ritu R. Gill | |
| 13:45-13:55 | Abstract by selection | |||
| 13:55-14:05 | Abstract by selection | |||
| 14:05-14:15 | Abstract by selection | |||
| 14:15-14:25 | Abstract by selection | |||
| 14:25-14:35 | Abstract by selection | |||
| 14:35-14:45 | Abstract by selection | |||
| 14:45-15:00 | Mesothelioma Staging Update | Anna Nowak | ||
| 15:00-15:15 | Discussion | |||
| 16:00-17:30 | Plenary IV: Immunotherapy - Checkpoint Blockade and Beyond | Arnaud Scherpereel Bruce Robinson | ||
| 16:00-16:15 | Immunotherapy in Mesothelioma – Beyond Checkpoint Blockade | Joachim Aerts | ||
| 16:15-16:30 | The Key Differences in the Immunologic Tumor Microenvironment in Mesothelioma vs Other Solid Cancers | Astero Klampatsa | ||
| 16:30-16:45 | Imaging in Immunotherapy: Special Considerations and Potential Pitfalls | Sharyn Katz | ||
| 16:45-17:00 | Mechanisms Underlying Checkpoint Inhibition Efficacy | Joost Lesterhuis | ||
| 17:00-17:10 | Abstract by selection | |||
| 17:10-17:20 | Abstract by selection | |||
| 17:20-17:30 | Discussion |
Saturday, March 28, 2020
| Time | Program | Chairs | Invited Speakers | |
| 7:30-8:15 | 07:30-08:15 | The Future of Mesothelioma - What Might the Next Decade Look Like For Our Patients? | Bruce Robinson Michele Carbone | |
| Panelists: Dean Fennell Michele Carbone Bruce Robinson Wee Loong (Melvin) Chin | ||||
| 8:15-8:45 | 8:15-8:45 | Morning Session II | Anna Nowak Sam Armato | |
| 8:45-10:15 | 8:45-10:15 | Plenary V: Cutting Edge 2020 | Anna Nowak Raphael Bueno | |
| 8:45-9:00 | CAR-T Cells | Prasad Adusumilli | ||
| 9:00-9:15 | Immunotherapy and Radiotherapy in Mesothelioma | Marc de Perrot | ||
| 9:15-9:30 | State of the Art Genomics 2020 | Nicola Waddell | ||
| 9:30-9:45 | Master Protocols for Salvage Therapy and the MIST Trial | Dean Fennell | ||
| 9:45-9:55 | Abstract by selection | |||
| 9:55-10:05 | Abstract by selection | |||
| 10:05-10:15 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 13: Biology and Novel Targets | Brett Hughes Dean Fennell | |
| 11:00-11:15 | Synthetic Lethality and DNA Repair | Derek Richard | ||
| 11:15-11:30 | NF2 | Yoshitaka Sekido | ||
| 11:30-11:40 | Abstract by selection | |||
| 11:40-11:50 | Abstract by selection | |||
| 11:50-12:00 | Abstract by selection | |||
| 12:00-12:10 | Abstract by selection | |||
| 12:10-12:20 | Abstract by selection | |||
| 12:20-12:30 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 14: Epidemiology and Asbestos Control | Bill Musk | |
| 11:00-11:15 | Chrysotile Toxicity and Why It Is Still Used | Jim teWaterNaude | ||
| 11:15-11:30 | The Asian Mesothelioma Epidemic | Seong-Kyu Kang | ||
| 11:30-11:45 | Mapping of Asbestos Containing Materials with Satellite Imagery | Jordan Gruber | ||
| 11:45-11:55 | Abstract by selection | |||
| 11:55-12:05 | Abstract by selection | |||
| 12:05-12:15 | Abstract by selection | |||
| 12:15-12:30 | Discussion | |||
| 11:00-12:30 | 11:00-12:30 | Parallel Mini-Symposia 15: Biomarkers and Genetics II | Tom John Steven Mutsaers | |
| 11:00-11:10 | Abstract by selection | |||
| 11:10-11:20 | Abstract by selection | |||
| 11:20-11:30 | Abstract by selection | |||
| 11:30-11:40 | Abstract by selection | |||
| 11:40-11:50 | Abstract by selection | |||
| 11:50-12:00 | Abstract by selection | |||
| 12:00-12:10 | Abstract by selection | |||
| 12:10-12:20 | Abstract by selection | |||
| 12:20-12:30 | Discussion | |||
| 14:00-15:30 | Plenary VI: Towards Tomorrow | Ken O'Byrne Andreas Rimner | ||
| 14:00-14:15 | Flash Radiation for Mesothelioma | Keith Cengel | ||
| 14:15-14:30 | Using Bioinformatics to Find Novel Immunotherapy Combinations | Wee Loong (Melvin) Chin | ||
| 14:30-14:45 | Precision Imaging: Molecular Targets to Guide Therapy in Mesothelioma | Roslyn Francis | ||
| 14:45-15:00 | MARS 3 and the Future of Surgery | David Waller | ||
| 15:00-15:10 | Abstract by selection | |||
| 15:10-15:20 | Abstract by selection | |||
| 15:20-15:30 | Discussion | |||
| 15:30-16:00 | 15:30-16:00 | Presidential Closing Address | ||
| 15:30-15:45 | Award Presentation | |||
| 15:45-16:00 | Closing Address |
-
The International Mesothelioma Interest Group (iMig) is an independent international group of scientists and clinicians working to understand, cure and prevent mesothelioma. -
CONFERENCE SECRETARIAT
International Conference Services
300-1201 West Pender Street, Vancouver, B.C, Canada V6E 2V2 Tel. [+1] 604-681-2153
Email: imig2021 at icsevents.com
Web: www.icsevents.com
© 2020 INTERNATIONAL MESOTHELIOMA INTEREST GROUP | Privacy Policy